Clear-cell dermal duct tumor is a benign adnexal neoplasm composed of dermal multiple solid islands of clear cells, displaying ductal differentiation. Histopathologically, lesions can be subdivided into 2 distinct subgroups: (1) "pure" clear-cell dermal duct tumors, entirely composed of clear cells, and (2) "mixed" clear-cell dermal duct tumors, showing an associated conventional poroid component. Such a subclassification may be significant for the differential diagnosis: the less frequent "mixed" variant may be more easily recognized because of the presence of poroid and cuticular cells and the more frequent "pure" variant is to be distinguished from many other benign and malignant dermal clear-cell epithelial tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000002595DOI Listing

Publication Analysis

Top Keywords

clear-cell dermal
16
dermal duct
16
duct tumor
8
clear cells
8
duct tumors
8
clear-cell
5
dermal
5
duct
4
tumor case
4
case report
4

Similar Publications

Article Synopsis
  • Diagnosing solitary pink skin lesions is challenging due to the overlap of clinical features among both benign (like cherry angiomas) and malignant lesions (such as basal cell carcinoma).
  • Reflectance confocal microscopy (RCM) improves diagnostic accuracy beyond traditional dermoscopy, offering better sensitivity and specificity for identifying these lesions.
  • Despite advancements, a definitive diagnosis still requires surgical excision and histopathological analysis to ensure correct treatment.
View Article and Find Full Text PDF

A female patient in her 70s with a newly diagnosed clear cell renal cell carcinoma (ccRCC) with osseous metastasis presented with sudden onset erythematous painful blistering skin lesions on the dorsum of both hands, with associated intermittent fever episodes. Blood tests showed elevated inflammatory marker levels (C reactive protein 257.8 mg/dL, leucocytes 17.

View Article and Find Full Text PDF

[Clinical, histological and genetic correlations in melanocytic tumours with chromosomal rearrangements].

Ann Pathol

February 2024

Service de biopathologie, centre Léon-Bérard, 28, promenade Léa-et-Napoléon-Bullukian, Lyon, France; Équipe labellisée Ligue contre le cancer, Inserm 1052, CNRS 5286, centre Léon-Bérard, Cancer Research Center of Lyon, université de Lyon, université Claude-Bernard Lyon 1, Lyon, France.

In some tumoral subtypes chromosomal translocations lead to an oncogenic chimeric protein acting as a tumorigenesis driver event. The main fusion model combines the promoter swapping of an inactivated tumor suppressor gene and a functional kinase that evades its regulatory system. The range of described fusions keeps growing in the 2023 WHO classification of melanocytic tumours.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!